British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy
- Posted on June 3, 2026
- By Bing News
- 0 Views
- 1 min read
British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy
June 4 (Reuters) - The UK cost-effectiveness watchdog on Thursday recommended AbbVie's "guided missile" cancer therapy, Elahere, for patients with a hard-to-treat form of ovarian cancer. The drug, Elahere, will be made available to patients under a confidential commercial agreement between AbbVie and the state-run National Health Service, the National Institute for Health and Care Excellence (
